Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of adagrasib alone or with pembrolizumab in KRAS G12C-mutant advanced non-small cell lung cancer
CTR20250645Phase 2Active
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adagrasib, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Aug 2022; status: active.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250645.